Schedule 13G Filing by C/M Capital Master Fund, LP and Others for Salarius Pharmaceuticals, Inc.

This Schedule 13G filing, submitted by C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno, reports their beneficial ownership of shares in Salarius Pharmaceuticals, Inc. The filing indicates that the shares were held by C/M Master Fund, with C/M Capital Partners acting as the investment manager. Thomas Walsh and Jonathan Juchno, as managing members of the general partner of C/M Capital Partners, disclaim beneficial ownership of the shares. The filing is made pursuant to Rule 13d-1(c) and includes a joint filing agreement among the reporting persons. The event date requiring this filing is October 7, 2025, and the filing was signed on October 14, 2025.